Hillary Dunlevy, MD
Infectious Disease · Aurora, CONPI 1811121569
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,075 of the $1,075 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Janssen Products, LP.
Across 2 payments — averaging $537.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Products, LP$1K
Across 1 payment — averaging $340,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$340K
What the payments were for
- Consulting fees$1,075100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Products, LP | 2 | $1,075 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Symtuza$1,075
How this compares
$1,075 in reported general payments places this provider in the 75th percentile of 146 infectious disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 67 | $259,204 |
| TivicayDolutegravir Sodium | 64 | $144,429 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 27 | $116,975 |
| DescovyEmtricitabine/Tenofov Alafenam | 55 | $113,095 |
| PrezcobixDarunavir/Cobicistat | 32 | $69,271 |
| DovatoDolutegravir Sodium/Lamivudine | 23 | $54,723 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $47,347 |
| PifeltroDoravirine | 13 | $23,013 |
| ValacyclovirValacyclovir Hcl | 16 | $993 |
| Pregabalin | 20 | $881 |
| Omeprazole | 17 | $497 |
| Duloxetine Hcl | 24 | $421 |
| Methadone Hcl | 11 | $299 |
| Rosuvastatin Calcium | 18 | $295 |
| Eszopiclone | 13 | $256 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Aurora
- Kristine ErlandsonAurora$88K
- Adriana WeinbergAurora$36K
- Carlos Franco ParedesAurora$25K
- Steven JohnsonAurora$24K
- Cynthia FirnhaberAurora$18K
- Edward StenehjemAurora$15K
- Thomas CampbellAurora$11K
- Andres Henao MartinezAurora$7K
- Edward JanoffAurora$3K
- Elizabeth ConnickAurora$724
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.